Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Young

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Annals of the Rheumatic Diseases|June 14, 2013
Health-related utility values of patients with primary Sjögren's syndrome and its predictorsDennis Lendrem, Sheryl Mitchell, Peter McMeekin, et al.
Swiss Medical Weekly|February 15, 2018
Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome RegistryAlexandre Dumusc, Wan-Fai Ng, Katherine James, et al.
Rheumatology (Oxford, England)|September 22, 2014
Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?Dennis Lendrem, Sheryl Mitchell, Peter McMeekin, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic PotentialLaszlo Radnai, Erica J Young, Carlos Kikuti, et al.
RMD Open|August 6, 2016
Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokinesNadia Howard Tripp, Jessica Tarn, Andini Natasari, et al.
Rheumatology (Oxford, England)|October 30, 2015
Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome RegistryClare Oni, Sheryl Mitchell, Katherine James, et al.
Cell|July 2, 2025
Development of clinically viable non-muscle myosin II small molecule inhibitorsLaszlo Radnai, Erica J Young, Carlos Kikuti, et al.
Rheumatology (Oxford, England)|October 3, 2017
Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome RegistryClare Oni, Sheryl Mitchell, Katherine James, et al.
RMD Open|June 7, 2019
Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndromeKate L Hackett, Kristen Davies, Jessica Tarn, et al.
Plos One|December 24, 2015
A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's SyndromeKatherine James, Shereen Al-Ali, Jessica Tarn, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Annals of the Rheumatic Diseases|June 14, 2013
Health-related utility values of patients with primary Sjögren's syndrome and its predictorsDennis Lendrem, Sheryl Mitchell, Peter McMeekin, et al.
Swiss Medical Weekly|February 15, 2018
Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome RegistryAlexandre Dumusc, Wan-Fai Ng, Katherine James, et al.
Rheumatology (Oxford, England)|September 22, 2014
Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?Dennis Lendrem, Sheryl Mitchell, Peter McMeekin, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic PotentialLaszlo Radnai, Erica J Young, Carlos Kikuti, et al.
RMD Open|August 6, 2016
Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokinesNadia Howard Tripp, Jessica Tarn, Andini Natasari, et al.
Rheumatology (Oxford, England)|October 30, 2015
Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome RegistryClare Oni, Sheryl Mitchell, Katherine James, et al.
Cell|July 2, 2025
Development of clinically viable non-muscle myosin II small molecule inhibitorsLaszlo Radnai, Erica J Young, Carlos Kikuti, et al.
Rheumatology (Oxford, England)|October 3, 2017
Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome RegistryClare Oni, Sheryl Mitchell, Katherine James, et al.
RMD Open|June 7, 2019
Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndromeKate L Hackett, Kristen Davies, Jessica Tarn, et al.
Plos One|December 24, 2015
A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's SyndromeKatherine James, Shereen Al-Ali, Jessica Tarn, et al.
Pageof 8